{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T05:06:53Z","timestamp":1769836013221,"version":"3.49.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,2,18]],"date-time":"2019-02-18T00:00:00Z","timestamp":1550448000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2017-02577"],"award-info":[{"award-number":["2017-02577"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2014-33867"],"award-info":[{"award-number":["2014-33867"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004348","name":"Stockholms L\u00e4ns Landsting","doi-asserted-by":"publisher","award":["20160378"],"award-info":[{"award-number":["20160378"]}],"id":[{"id":"10.13039\/501100004348","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004348","name":"Stockholms L\u00e4ns Landsting","doi-asserted-by":"publisher","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/501100004348","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004348","name":"Stockholms L\u00e4ns Landsting","doi-asserted-by":"publisher","award":["ALF 20170038"],"award-info":[{"award-number":["ALF 20170038"]}],"id":[{"id":"10.13039\/501100004348","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","award":["115766"],"award-info":[{"award-number":["115766"]}],"id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007949","name":"Reumatikerf\u00f6rbundet","doi-asserted-by":"publisher","award":["R-755861"],"award-info":[{"award-number":["R-755861"]}],"id":[{"id":"10.13039\/501100007949","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007949","name":"Reumatikerf\u00f6rbundet","doi-asserted-by":"publisher","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/501100007949","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007949","name":"Reumatikerf\u00f6rbundet","doi-asserted-by":"publisher","award":["R-73931"],"award-info":[{"award-number":["R-73931"]}],"id":[{"id":"10.13039\/501100007949","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The AstraZeneca-Karolinska Institutet Joint Research Program in Translational Science","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}]},{"DOI":"10.13039\/501100001858","name":"VINNOVA","doi-asserted-by":"publisher","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/501100001858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003793","name":"Hj\u00e4rt-Lungfonden","doi-asserted-by":"publisher","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/501100003793","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007857","name":"Stiftelsen Konung Gustaf V:s 80-\u00e5rsfond","doi-asserted-by":"publisher","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/501100007857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007435","name":"\u00c5ke Wiberg Stiftelse","doi-asserted-by":"publisher","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/100007435","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009734","name":"Alex och Eva Wallstr\u00f6ms Stiftelse f\u00f6r Vetenskaplig Forskning och Utbildning","doi-asserted-by":"publisher","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/501100009734","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004047","name":"Karolinska Institutet","doi-asserted-by":"publisher","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006350","name":"Stiftelsen Clas Groschinskys Minnesfond","doi-asserted-by":"publisher","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/501100006350","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007687","name":"Svenska L\u00e4kares\u00e4llskapet","doi-asserted-by":"publisher","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/501100007687","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ingegerd Johansson's foundation","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}]},{"DOI":"10.13039\/501100009791","name":"Stiftelsen Apotekare Hedbergs Fond f\u00f6r Medicinsk Forskning","doi-asserted-by":"publisher","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/501100009791","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007508","name":"Stiftelsen Sigurd and Elsa Goljes Minne","doi-asserted-by":"publisher","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/501100007508","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13075-019-1836-8","type":"journal-article","created":{"date-parts":[[2019,2,18]],"date-time":"2019-02-18T12:03:51Z","timestamp":1550491431000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Two subgroups in systemic lupus erythematosus with features of antiphospholipid or Sj\u00f6gren\u2019s syndrome differ in molecular signatures and treatment perspectives"],"prefix":"10.1186","volume":"21","author":[{"given":"Helena","family":"Idborg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arash","family":"Zandian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann-Sofi","family":"Sandberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Nilsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerstin","family":"Elvin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lennart","family":"Truedsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Azita","family":"Sohrabian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johan","family":"R\u00f6nnelid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Mo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgia","family":"Grosso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marika","family":"Kvarnstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iva","family":"Gunnarsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janne","family":"Lehti\u00f6","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Nilsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabet","family":"Svenungsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Per-Johan","family":"Jakobsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,2,18]]},"reference":[{"issue":"Suppl 1","key":"1836_CR1","doi-asserted-by":"publisher","first-page":"i64","DOI":"10.1136\/ard.2010.142208","volume":"70","author":"BH Hahn","year":"2011","unstructured":"Hahn BH. Targeted therapies in systemic lupus erythematosus: successes, failures and future. Ann Rheum Dis. 2011;70(Suppl 1):i64.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"1836_CR2","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1111\/j.1756-185X.2012.01764.x","volume":"15","author":"R Herbst","year":"2012","unstructured":"Herbst R, Liu Z, Jallal B, Yao Y. Biomarkers for systemic lupus erythematosus. Int J Rheum Dis. 2012;15(5):433\u201344.","journal-title":"Int J Rheum Dis"},{"issue":"4","key":"1836_CR3","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.trsl.2012.01.021","volume":"159","author":"JM Ahearn","year":"2012","unstructured":"Ahearn JM, Liu C-C, Kao AH, Manzi S. Biomarkers for systemic lupus erythematosus. Transl Res. 2012;159(4):326\u201342.","journal-title":"Transl Res"},{"issue":"2","key":"1836_CR4","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","volume":"4","author":"S Miyakis","year":"2006","unstructured":"Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RHWM, De Groot PG, Koike T, Meroni PL, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295\u2013306.","journal-title":"J Thromb Haemost"},{"key":"1836_CR5","doi-asserted-by":"publisher","unstructured":"Gustafsson JT, Gunnarsson I, Kallberg H, Pettersson S, Zickert A, Vikerfors A, Moller S, Ronnelid J, Elvin K, Svenungsson E. Cigarette smoking, antiphospholipid antibodies and vascular events in systemic lupus erythematosus. Ann Rheum Dis. 2015;74(8):1537-43. https:\/\/doi.org\/10.1136\/annrheumdis-2013-205159 .","DOI":"10.1136\/annrheumdis-2013-205159"},{"issue":"8","key":"1836_CR6","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1093\/aje\/kws130","volume":"176","author":"LS Magder","year":"2012","unstructured":"Magder LS, Petri M. Incidence of and risk factors for adverse cardiovascular events among patients with systemic lupus erythematosus. Am J Epidemiol. 2012;176(8):708\u201319.","journal-title":"Am J Epidemiol"},{"issue":"2","key":"1836_CR7","doi-asserted-by":"publisher","first-page":"R46","DOI":"10.1186\/ar3759","volume":"14","author":"JT Gustafsson","year":"2012","unstructured":"Gustafsson JT, Simard JF, Gunnarsson I, Elvin K, Lundberg IE, Hansson L-O, Larsson A, Svenungsson E. Risk factors for cardiovascular mortality in patients with systemic lupus erythematosus, a prospective cohort study. Arthritis Res Ther. 2012;14(2):R46.","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"1836_CR8","doi-asserted-by":"publisher","first-page":"4003","DOI":"10.1002\/art.21414","volume":"52","author":"CH To","year":"2005","unstructured":"To CH, Petri M. Is antibody clustering predictive of clinical subsets and damage in systemic lupus erythematosus? Arthritis Rheum. 2005;52(12):4003\u201310.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"1836_CR9","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.3899\/jrheum.130984","volume":"41","author":"B Artim-Esen","year":"2014","unstructured":"Artim-Esen B, Cene E, Sahinkaya Y, Ertan S, Pehlivan O, Kamali S, G\u00fcl A, Ocal L, Aral O, Inan\u00e7 M. Cluster analysis of autoantibodies in 852 patients with systemic lupus erythematosus from a single center. J Rheumatol. 2014;41(7):1304.","journal-title":"J Rheumatol"},{"issue":"3","key":"1836_CR10","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1093\/rheumatology\/kes252","volume":"52","author":"A Vikerfors","year":"2013","unstructured":"Vikerfors A, Johansson A-B, Gustafsson JT, J\u00f6nsen A, Leonard D, Zickert A, Nordmark G, Sturfelt G, Bengtsson A, R\u00f6nnblom L, et al. Clinical manifestations and anti-phospholipid antibodies in 712 patients with systemic lupus erythematosus: evaluation of two diagnostic assays. Rheumatology. 2013;52(3):501\u20139.","journal-title":"Rheumatology"},{"issue":"11","key":"1836_CR11","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1002\/art.1780251101","volume":"25","author":"EM Tan","year":"1982","unstructured":"Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25(11):1271\u20137.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"1836_CR12","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.berh.2005.03.010","volume":"19","author":"B Griffiths","year":"2005","unstructured":"Griffiths B, Mosca M, Gordon C. Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices. Best Pract Res Clin Rheumatol. 2005;19(5):685\u2013708.","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"1","key":"1836_CR13","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/j.1365-3083.1992.tb02837.x","volume":"35","author":"K Nilsson Ekdahl","year":"1992","unstructured":"Nilsson Ekdahl K, Nilsson B, Pekna M, Nilsson UR. Generation of iC3 at the interface between blood and gas. Scand J Immunol. 1992;35(1):85\u201391.","journal-title":"Scand J Immunol"},{"issue":"2","key":"1836_CR14","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1111\/j.1365-3083.1985.tb01871.x","volume":"22","author":"TE Mollnes","year":"1985","unstructured":"Mollnes TE, Lea T, Fr\u00f8land SS, Harboe M. Quantification of the terminal complement complex in human plasma by an enzyme-linked immunosorbent assay based on monoclonal antibodies against a neoantigen of the complex. Scand J Immunol. 1985;22(2):197\u2013202.","journal-title":"Scand J Immunol"},{"key":"1836_CR15","first-page":"263","volume":"2","author":"NR Cooper","year":"1988","unstructured":"Cooper NR. Laboratory investigation of complement proteins and complement receptors. Baillieres Clin Immunol Allergy. 1988;2:263\u201393.","journal-title":"Baillieres Clin Immunol Allergy"},{"issue":"11","key":"1836_CR16","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1136\/ard.2011.150326","volume":"70","author":"BW Higgs","year":"2011","unstructured":"Higgs BW, Liu Z, White B, Zhu W, White WI, Morehouse C, Brohawn P, Kiener PA, Richman L, Fiorentino D, et al. Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway. Ann Rheum Dis. 2011;70(11):2029.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"1836_CR17","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1038\/nbt1210-1248","volume":"28","author":"M Uhlen","year":"2010","unstructured":"Uhlen M, Hober S, Wernerus H, Bj\u00f6rling L, Ponten F, Oksvold P, Fagerberg L, Lundberg E, Jonasson K, Forsberg M, et al. Towards a knowledge-based human protein atlas. Nat Biotechnol. 2010;28(12):1248\u201350.","journal-title":"Nat Biotechnol"},{"key":"1836_CR18","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/978-1-4614-7209-4_8","volume":"1023","author":"K Drobin","year":"2013","unstructured":"Drobin K, Nilsson P, Schwenk JM. Highly multiplexed antibody suspension bead arrays for plasma protein profiling. Method Mol Biol. 2013;1023:137.","journal-title":"Method Mol Biol"},{"issue":"3","key":"1836_CR19","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1080\/10618600.1996.10474713","volume":"5","author":"R Ihaka","year":"1996","unstructured":"Ihaka R, Gentleman R. R: a language for data analysis and graphics. J Comput Graph Stat. 1996;5(3):299\u2013314.","journal-title":"J Comput Graph Stat"},{"issue":"6","key":"1836_CR20","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1136\/ard.61.6.554","volume":"61","author":"C Vitali","year":"2002","unstructured":"Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, Daniels TE, Fox PC, Fox RI, Kassan SS, et al. Classification criteria for Sj\u00f6gren's syndrome: a revised version of the European criteria proposed by the American-European consensus group. Ann Rheum Dis. 2002;61(6):554.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"1836_CR21","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1038\/nrrheum.2012.75","volume":"8","author":"G Sturfelt","year":"2012","unstructured":"Sturfelt G, Truedsson L. Complement in the immunopathogenesis of rheumatic disease. Nat Rev Rheumatol. 2012;8(8):458\u201368.","journal-title":"Nat Rev Rheumatol"},{"issue":"C","key":"1836_CR22","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.clim.2017.09.013","volume":"183","author":"C Gr\u00f6nwall","year":"2017","unstructured":"Gr\u00f6nwall C, Hardt U, Gustafsson JT, Elvin K, Jensen-Urstad K, Kvarnstr\u00f6m M, Grosso G, R\u00f6nnelid J, Padykov L, Gunnarsson I, et al. Depressed serum IgM levels in SLE are restricted to defined subgroups. Clin Immunol. 2017;183(C):304\u201315.","journal-title":"Clin Immunol"},{"issue":"1","key":"1836_CR23","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1097\/RHU.0b013e31823ecbdf","volume":"18","author":"Q Yao","year":"2012","unstructured":"Yao Q, Altman RD, Wang X. Systemic lupus erythematosus with Sjogren syndrome compared to systemic lupus erythematosus alone: a meta-analysis. J Clin Rheumatol. 2012;18(1):28\u201332.","journal-title":"J Clin Rheumatol"},{"issue":"3","key":"1836_CR24","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1002\/art.20093","volume":"50","author":"MN Manoussakis","year":"2004","unstructured":"Manoussakis MN, Georgopoulou C, Zintzaras E, Spyropoulou M, Stavropoulou A, Skopouli FN, Moutsopoulos HM. Sjogren's syndrome associated with systemic lupus erythematosus: clinical and laboratory profiles and comparison with primary Sjogren's syndrome. Arthritis Rheum. 2004;50(3):882\u201391.","journal-title":"Arthritis Rheum"},{"issue":"1\u20132","key":"1836_CR25","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jaut.2012.03.001","volume":"39","author":"V-K Bournia","year":"2012","unstructured":"Bournia V-K, Vlachoyiannopoulos PG. Subgroups of Sj\u00f6gren syndrome patients according to serological profiles. J Autoimmun. 2012;39(1\u20132):15\u201326.","journal-title":"J Autoimmun"},{"issue":"6","key":"1836_CR26","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1136\/annrheumdis-2013-203622","volume":"73","author":"D Erkan","year":"2014","unstructured":"Erkan D, Willis R, Murthy VL, Basra G, Vega J, Ruiz-Limon P, Carrera AL, Papalardo E, Martinez-Martinez LA, Gonzalez EB, et al. A prospective open-label pilot study of fluvastatin on proinflammatory and prothrombotic biomarkers in antiphospholipid antibody positive patients. Ann Rheum Dis. 2014;73(6):1176\u201380.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"1836_CR27","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1177\/0961203315604040","volume":"25","author":"SA Just","year":"2016","unstructured":"Just SA, Nybo M, Laustrup H, Hansen IMJ, Junker P, Vinholt PJ. Single test isolated lupus anticoagulant positivity is associated with increased plasma levels of inflammatory markers and dyslipidemia. Lupus. 2016;25(3):241\u20137.","journal-title":"Lupus"},{"issue":"10","key":"1836_CR28","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/j.autrev.2016.07.020","volume":"15","author":"K Oku","year":"2016","unstructured":"Oku K, Nakamura H, Kono M, Ohmura K, Kato M, Bohgaki T, Horita T, Yasuda S, Amengual O, Atsumi T. Complement and thrombosis in the antiphospholipid syndrome. Autoimmun Rev. 2016;15(10):1001\u20134.","journal-title":"Autoimmun Rev"},{"issue":"2","key":"1836_CR29","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/sji.12445","volume":"84","author":"L Garabet","year":"2016","unstructured":"Garabet L, Gilboe IM, Mowinckel MC, Jacobsen AF, Mollnes TE, Sandset PM, Jacobsen EM. Antiphospholipid antibodies are associated with low levels of complement C3 and C4 in patients with systemic lupus erythematosus. Scand J Immunol. 2016;84(2):95\u20139.","journal-title":"Scand J Immunol"},{"issue":"5","key":"1836_CR30","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1177\/0961203308090025","volume":"17","author":"JE Salmon","year":"2008","unstructured":"Salmon JE, de Groot PG. Pathogenic role of antiphospholipid antibodies. Lupus. 2008;17(5):405\u201311.","journal-title":"Lupus"},{"issue":"8","key":"1836_CR31","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1002\/art.34440","volume":"64","author":"I Shapira","year":"2012","unstructured":"Shapira I, Andrade D, Allen SL, Salmon JE. Brief report: induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab. Arthritis Rheum. 2012;64(8):2719.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"1836_CR32","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1002\/art.22581","volume":"56","author":"S Nakayamada","year":"2007","unstructured":"Nakayamada S, Saito K, Nakano K, Tanaka Y. Activation signal transduction by beta1 integrin in T cells from patients with systemic lupus erythematosus. Arthritis Rheum. 2007;56(5):1559.","journal-title":"Arthritis Rheum"},{"issue":"4","key":"1836_CR33","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.trsl.2012.01.020","volume":"159","author":"W Ju","year":"2012","unstructured":"Ju W, Smith S, Kretzler M. Genomic biomarkers for chronic kidney disease. Transl Res. 2012;159(4):290\u2013302.","journal-title":"Transl Res"},{"key":"1836_CR34","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.plipres.2017.01.002","volume":"66","author":"S Rodriguez-Cuenca","year":"2017","unstructured":"Rodriguez-Cuenca S, Pellegrinelli V, Campbell M, Oresic M, Vidal-Puig A. Sphingolipids and glycerophospholipids \u2013 the \u201cying and yang\u201d of lipotoxicity in metabolic diseases. Prog Lipid Res. 2017;66:14\u201329.","journal-title":"Prog Lipid Res"},{"issue":"5","key":"1836_CR35","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/S1043-6618(03)00051-3","volume":"47","author":"B Cinque","year":"2003","unstructured":"Cinque B, Di Marzio L, Centi C, Di Rocco C, Riccardi C, Grazia Cifone M. Sphingolipids and the immune system. Pharmacol Res. 2003;47(5):421\u201337.","journal-title":"Pharmacol Res"},{"issue":"11","key":"1836_CR36","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.tem.2016.07.005","volume":"27","author":"L Sasset","year":"2016","unstructured":"Sasset L, Zhang Y, Dunn TM, Di Lorenzo A. Sphingolipid De novo biosynthesis: a rheostat of cardiovascular homeostasis. Trends Endocrinol Metab. 2016;27(11):807\u201319.","journal-title":"Trends Endocrinol Metab"},{"issue":"13","key":"1836_CR37","doi-asserted-by":"publisher","first-page":"6989","DOI":"10.1074\/jbc.M115.691212","volume":"291","author":"D Gosejacob","year":"2016","unstructured":"Gosejacob D, J\u00e4ger PS, Vom Dorp K, Frejno M, Carstensen AC, K\u00f6hnke M, Degen J, D\u00f6rmann P, Hoch M. Ceramide synthase 5 is essential to maintain C16:0-ceramide pools and contributes to the development of diet-induced obesity. J Biol Chem. 2016;291(13):6989.","journal-title":"J Biol Chem"},{"issue":"10","key":"1836_CR38","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1177\/0961203316686707","volume":"26","author":"A Checa","year":"2017","unstructured":"Checa A, Idborg H, Zandian A, Sar DG, Surowiec I, Trygg J, Svenungsson E, Jakobsson PJ, Nilsson P, Gunnarsson I, et al. Dysregulations in circulating sphingolipids associate with disease activity indices in female patients with systemic lupus erythematosus: a cross-sectional study. Lupus. 2017;26(10):1023\u201333.","journal-title":"Lupus"},{"key":"1836_CR39","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.vph.2015.05.001","volume":"73","author":"G Vilahur","year":"2015","unstructured":"Vilahur G, Badimon L. Biological actions of pentraxins. Vasc Pharmacol. 2015;73:38\u201344.","journal-title":"Vasc Pharmacol"},{"issue":"6","key":"1836_CR40","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1007\/s10875-005-7828-2","volume":"25","author":"M Kravitz","year":"2005","unstructured":"Kravitz M, Pitashny M, Shoenfeld Y. Protective molecules\u2013C-reactive protein (CRP), serum amyloid P (SAP), Pentraxin3 (PTX3), mannose-binding lectin (MBL), and apolipoprotein A1 (Apo A1), and their autoantibodies: prevalence and clinical significance in autoimmunity. J Clin Immunol. 2005;25(6):582\u201391.","journal-title":"J Clin Immunol"},{"issue":"19","key":"1836_CR41","doi-asserted-by":"publisher","first-page":"e834","DOI":"10.1097\/MD.0000000000000834","volume":"94","author":"J Lin","year":"2015","unstructured":"Lin J, Li N, Chen H, Liu C, Yang B, Ou Q. Serum Cyr61 is associated with clinical disease activity and inflammation in patients with systemic lupus erythematosus. Medicine. 2015;94(19):e834.","journal-title":"Medicine"},{"issue":"3","key":"1836_CR42","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1089\/107999002753675721","volume":"22","author":"A Kaba","year":"2002","unstructured":"Kaba A, Ilunga A-JL, Achour A, Zagury J-F, Chany C. The interferon antagonist sarcolectin in the progress of HIV-1 infection and in AIDS. J Interferon Cytokine Res. 2002;22(3):305.","journal-title":"J Interferon Cytokine Res"},{"issue":"4","key":"1836_CR43","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1002\/art.20998","volume":"52","author":"U B\u00e5ve","year":"2005","unstructured":"B\u00e5ve U, Nordmark G, L\u00f6vgren T, R\u00f6nnelid J, Cajander S, Ml E, Alm GV, R\u00f6nnblom L. Activation of the type I interferon system in primary Sj\u00f6gren's syndrome: a possible etiopathogenic mechanism. Arthritis Rheum. 2005;52(4):1185\u201395.","journal-title":"Arthritis Rheum"},{"key":"1836_CR44","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jaut.2015.07.002","volume":"63","author":"A Nezos","year":"2015","unstructured":"Nezos A, Gravani F, Tassidou A, Kapsogeorgou EK, Voulgarelis M, Koutsilieris M, Crow MK, Mavragani CP. Type I and II interferon signatures in Sjogren's syndrome pathogenesis: contributions in distinct clinical phenotypes and Sjogren's related lymphomagenesis. J Autoimmun. 2015;63:47\u201358.","journal-title":"J Autoimmun"},{"issue":"5","key":"1836_CR45","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1136\/annrheumdis-2012-201381","volume":"72","author":"Z Brkic","year":"2013","unstructured":"Brkic Z, Maria NI, van Helden-Meeuwsen CG, van de Merwe JP, van Daele PL, Dalm VA, Wildenberg ME, Beumer W, Drexhage HA, Versnel MA. Prevalence of interferon type I signature in CD14 monocytes of patients with Sj\u00f6gren's syndrome and association with disease activity and BAFF gene expression. Ann Rheum Dis. 2013;72(5):728.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"1836_CR46","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1136\/annrheumdis-2016-209442","volume":"76","author":"RC Grenn","year":"2017","unstructured":"Grenn RC, Yalavarthi S, Gandhi AA, Kazzaz NM, N\u00fa\u00f1ez-\u00c1lvarez C, Hern\u00e1ndez-Ram\u00edrez D, Cabral AR, McCune WJ, Bockenstedt PL, Knight JS. Endothelial progenitor dysfunction associates with a type I interferon signature in primary antiphospholipid syndrome. Ann Rheum Dis. 2017;76(2):450.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1836_CR47","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s13075-017-1344-7","volume":"19","author":"V Oke","year":"2017","unstructured":"Oke V, Brauner S, Larsson A, Gustafsson J, Zickert A, Gunnarsson I, Svenungsson E. IFN-\u03bb1 with Th17 axis cytokines and IFN-\u03b1 define different subsets in systemic lupus erythematosus (SLE). Arthritis Res Ther. 2017;19(1):139.","journal-title":"Arthritis Res Ther"},{"issue":"39","key":"1836_CR48","doi-asserted-by":"publisher","first-page":"33811","DOI":"10.1074\/jbc.M111.270207","volume":"286","author":"RAR Piganis","year":"2011","unstructured":"Piganis RAR, De Weerd NA, Gould JA, Schindler CW, Mansell A, Nicholson SE, Hertzog PJ. Suppressor of cytokine signaling (SOCS) 1 inhibits type I interferon (IFN) signaling via the interferon alpha receptor (IFNAR1)-associated tyrosine kinase Tyk2. J Biol Chem. 2011;286(39):33811.","journal-title":"J Biol Chem"},{"issue":"10","key":"1836_CR49","doi-asserted-by":"publisher","first-page":"e1002341","DOI":"10.1371\/journal.pgen.1002341","volume":"7","author":"DS Cunninghame Graham","year":"2011","unstructured":"Cunninghame Graham DS, Morris DL, Bhangale TR, Criswell LA, Syv\u00e4nen A-C, R\u00f6nnblom L, Behrens TW, Graham RR, Vyse TJ. Association of NCF2 , IKZF1 , IRF8 , IFIH1 , and TYK2 with Systemic Lupus Erythematosus (Association of Five New Genes with SLE). PLoS Genet. 2011;7(10):e1002341.","journal-title":"PLoS Genet"},{"issue":"2","key":"1836_CR50","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.scr.2015.08.003","volume":"15","author":"J Ignatius Irudayam","year":"2015","unstructured":"Ignatius Irudayam J, Contreras D, Spurka L, Subramanian A, Allen J, Ren S, Kanagavel V, Nguyen Q, Ramaiah A, Ramamoorthy K, et al. Characterization of type I interferon pathway during hepatic differentiation of human pluripotent stem cells and hepatitis C virus infection. Stem Cell Res. 2015;15(2):354\u201364.","journal-title":"Stem Cell Res"},{"issue":"2","key":"1836_CR51","doi-asserted-by":"publisher","first-page":"590","DOI":"10.4049\/jimmunol.1501032","volume":"197","author":"CM Minutti","year":"2016","unstructured":"Minutti CM, Garc\u00eda-Fojeda B, S\u00e1enz A, de Las C-EM, Guillamat-Prats R, de Lorenzo A, Serrano-Mollar A, Corb\u00ed \u00c1L, Casals C. Surfactant Protein A Prevents IFN-\u03b3\/IFN-\u03b3 Receptor Interaction and Attenuates Classical Activation of Human Alveolar Macrophages. J Immunol. 2016;197(2):590.","journal-title":"J Immunol"},{"issue":"14","key":"1836_CR52","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1101\/gad.1323805","volume":"19","author":"Z Yan","year":"2005","unstructured":"Yan Z, Cui K, Murray DM, Ling C, Xue Y, Gerstein A, Parsons R, Zhao K, Wang W. PBAF chromatin-remodeling complex requires a novel specificity subunit, BAF200, to regulate expression of selective interferon-responsive genes. Genes Dev. 2005;19(14):1662.","journal-title":"Genes Dev"},{"issue":"5","key":"1836_CR53","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1016\/j.jmb.2007.02.085","volume":"368","author":"S Duquerroy","year":"2007","unstructured":"Duquerroy S, Stura EA, Bressanelli S, Fabiane SM, Vaney MC, Beale D, Hamon M, Casali P, Rey FA, Sutton BJ, et al. Crystal structure of a human autoimmune complex between IgM rheumatoid factor RF61 and IgG1 fc reveals a novel epitope and evidence for affinity maturation. J Mol Biol. 2007;368(5):1321\u201331.","journal-title":"J Mol Biol"},{"issue":"D1","key":"1836_CR54","doi-asserted-by":"publisher","first-page":"D158","DOI":"10.1093\/nar\/gkw1099","volume":"45","author":"The UniProt Consortium","year":"2017","unstructured":"The UniProt Consortium. UniProt: the universal protein knowledgebase. Nucleic Acids Res. 2017;45(D1):D158\u201369.","journal-title":"Nucleic Acids Res"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-019-1836-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13075-019-1836-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-019-1836-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,14]],"date-time":"2024-07-14T21:32:29Z","timestamp":1720992749000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-019-1836-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,18]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1836"],"URL":"https:\/\/doi.org\/10.1186\/s13075-019-1836-8","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,18]]},"assertion":[{"value":"3 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The ethical board at the Karolinska University Hospital approved the study (reference number 03-556). All study participants gave written informed consent to participate.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All coauthors have declared consent for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"LT has consultancies for Euro Diagnostica (<\u2009$10,000), JM is employed by AstraZeneca, and JR is a member of the scientific advisory board for Phadia\/Thermo Fisher. This study was supported by the AstraZeneca-Karolinska Institutet Joint Research Program in Translational Science. Other authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"62"}}